دورية أكاديمية
أعرض في EDS

Molecular signature incorporating the immune microenvironment enhances thyroid cancer outcome prediction.

التفاصيل البيبلوغرافية
العنوان: Molecular signature incorporating the immune microenvironment enhances thyroid cancer outcome prediction.
المؤلفون: Xu GJ; Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA., Loberg MA; Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA., Gallant JN; Department of Otolaryngology - Head & Neck Surgery, Vanderbilt University Medical Center, Nashville, TN, USA., Sheng Q; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA., Chen SC; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA., Lehmann BD; Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA.; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA., Shaddy SM; Department of Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, WA, USA., Tigue ML; Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA., Phifer CJ; Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA., Wang L; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA., Saab-Chalhoub MW; Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA., Dehan LM; Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA., Wei Q; Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN, USA., Chen R; Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN, USA., Li B; Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN, USA., Kim CY; Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA., Ferguson DC; Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA., Netterville JL; Department of Otolaryngology - Head & Neck Surgery, Vanderbilt University Medical Center, Nashville, TN, USA.; Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA., Rohde SL; Department of Otolaryngology - Head & Neck Surgery, Vanderbilt University Medical Center, Nashville, TN, USA.; Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA., Solórzano CC; Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA.; Department of Surgery, Vanderbilt University Medical Center, Nashville, TN, USA., Bischoff LA; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA., Baregamian N; Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA.; Department of Surgery, Vanderbilt University Medical Center, Nashville, TN, USA., Shaver AC; Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA., Mehrad M; Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA., Ely KA; Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA., Byrne DW; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA., Stricker TP; Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA., Murphy BA; Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA.; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA., Choe JH; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA., Kagohara LT; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.; Convergence Institute, Johns Hopkins University, Baltimore, MD, USA.; Bloomberg-Kimmel Immunotherapy Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Jaffee EM; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.; Convergence Institute, Johns Hopkins University, Baltimore, MD, USA.; Bloomberg-Kimmel Immunotherapy Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Huang EC; Department of Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, WA, USA., Ye F; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA.; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA., Lee E; Department of Cell and Developmental Biology, Vanderbilt University, Nashville, TN, USA.; Department of Pharmacology, Vanderbilt University, Nashville, TN, USA.; Department of Cancer Biology, Vanderbilt University, Nashville, TN, USA., Weiss VL; Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.; Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA.; Department of Pharmacology, Vanderbilt University, Nashville, TN, USA.; Department of Cancer Biology, Vanderbilt University, Nashville, TN, USA.
المصدر: Cell genomics [Cell Genom] 2023 Sep 14; Vol. 3 (10), pp. 100409. Date of Electronic Publication: 2023 Sep 14 (Print Publication: 2023).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier, Inc Country of Publication: United States NLM ID: 9918284260106676 Publication Model: eCollection Cited Medium: Internet ISSN: 2666-979X (Electronic) Linking ISSN: 2666979X NLM ISO Abbreviation: Cell Genom Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [New York] : Elsevier, Inc., [2021]-
مستخلص: Genomic and transcriptomic analysis has furthered our understanding of many tumors. Yet, thyroid cancer management is largely guided by staging and histology, with few molecular prognostic and treatment biomarkers. Here, we utilize a large cohort of 251 patients with 312 samples from two tertiary medical centers and perform DNA/RNA sequencing, spatial transcriptomics, and multiplex immunofluorescence to identify biomarkers of aggressive thyroid malignancy. We identify high-risk mutations and discover a unique molecular signature of aggressive disease, the Molecular Aggression and Prediction (MAP) score, which provides improved prognostication over high-risk mutations alone. The MAP score is enriched for genes involved in epithelial de-differentiation, cellular division, and the tumor microenvironment. The MAP score also identifies aggressive tumors with lymphocyte-rich stroma that may benefit from immunotherapy. Future clinical profiling of the stromal microenvironment of thyroid cancer could improve prognostication, inform immunotherapy, and support development of novel therapeutics for thyroid cancer and other stroma-rich tumors.
Competing Interests: E.L. is a co-founder of StemSynergy Therapeutics, a company that seeks to develop inhibitors of major signaling pathways (including the Wnt pathway) for the treatment of cancer. E.M.J. reports other support from Abmeta, other support from Adventris, personal fees from Achilles, personal fees from DragonFly, personal fees from Parker Institute, personal fees from Surge, grants from Lustgarten, grants from Genentech, personal fees from Mestag, personal fees from Medical Home Group, grants from BMS, and grants from Break Through Cancer outside the submitted work.
(© 2023 The Author(s).)
References: Cell. 2014 Oct 23;159(3):676-90. (PMID: 25417114)
J Clin Invest. 2016 Mar 1;126(3):1052-66. (PMID: 26878173)
Nat Methods. 2015 May;12(5):453-7. (PMID: 25822800)
Nat Rev Endocrinol. 2011 Aug 30;7(10):569-80. (PMID: 21878896)
Genome Biol. 2016 Oct 20;17(1):218. (PMID: 27765066)
Int J Endocrinol. 2014;2014:790834. (PMID: 25214840)
Nucleic Acids Res. 2020 Jul 2;48(W1):W509-W514. (PMID: 32442275)
JAMA Oncol. 2019 Feb 1;5(2):204-212. (PMID: 30419129)
J Natl Cancer Inst. 2003 Apr 16;95(8):625-7. (PMID: 12697856)
J Clin Endocrinol Metab. 2019 Aug 1;104(8):3557-3575. (PMID: 30882858)
Bioinformatics. 2014 Apr 1;30(7):923-30. (PMID: 24227677)
Clin Cancer Res. 2018 Jul 1;24(13):3059-3068. (PMID: 29615459)
Protein Sci. 2022 Jan;31(1):8-22. (PMID: 34717010)
J Clin Endocrinol Metab. 2017 Feb 1;102(2):625-633. (PMID: 27732329)
Cancer. 2006 Mar 15;106(6):1286-95. (PMID: 16470605)
Nucleic Acids Res. 2021 Jan 8;49(D1):D916-D923. (PMID: 33270111)
Genome Res. 2018 Nov;28(11):1747-1756. (PMID: 30341162)
Bioinformatics. 2010 Mar 1;26(5):589-95. (PMID: 20080505)
Nat Rev Cancer. 2013 Mar;13(3):184-99. (PMID: 23429735)
Nat Commun. 2023 Feb 2;14(1):568. (PMID: 36732531)
Nat Med. 2019 May;25(5):744-750. (PMID: 31011206)
Genome Res. 2010 Sep;20(9):1297-303. (PMID: 20644199)
Genome Biol. 2014;15(12):550. (PMID: 25516281)
Nature. 2020 May;581(7809):434-443. (PMID: 32461654)
Thyroid. 2021 Jul;31(7):1076-1085. (PMID: 33509020)
Cancers (Basel). 2020 Jul 20;12(7):. (PMID: 32698386)
Cell. 2021 Jun 24;184(13):3573-3587.e29. (PMID: 34062119)
Nat Genet. 2000 May;25(1):25-9. (PMID: 10802651)
J Clin Endocrinol Metab. 2008 May;93(5):1600-8. (PMID: 18270258)
Nat Med. 2018 Oct;24(10):1550-1558. (PMID: 30127393)
Nature. 2016 Aug 17;536(7616):285-91. (PMID: 27535533)
Carcinogenesis. 2014 Aug;35(8):1780-7. (PMID: 24608042)
Cancer. 2018 Apr 15;124(8):1682-1690. (PMID: 29345728)
J Clin Invest. 2023 Jun 1;133(11):. (PMID: 37053016)
Sci Rep. 2020 May 15;10(1):8031. (PMID: 32415114)
J Oncol. 2011;2011:542358. (PMID: 21772843)
Nucleic Acids Res. 2010 Sep;38(16):e164. (PMID: 20601685)
Cancer Res. 2014 Jun 1;74(11):2913-21. (PMID: 24840647)
Cancers (Basel). 2021 Feb 20;13(4):. (PMID: 33672707)
Nat Commun. 2019 Jun 24;10(1):2764. (PMID: 31235699)
JAMA. 2017 Apr 4;317(13):1338-1348. (PMID: 28362912)
Pharmacol Ther. 2021 May;221:107753. (PMID: 33259885)
Cell Syst. 2015 Dec 23;1(6):417-425. (PMID: 26771021)
Physiol Rev. 2021 Jan 1;101(1):147-176. (PMID: 32466724)
Cancer Discov. 2012 May;2(5):401-4. (PMID: 22588877)
BMC Bioinformatics. 2011 Aug 04;12:323. (PMID: 21816040)
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50. (PMID: 16199517)
Thyroid. 2020 Oct;30(10):1505-1517. (PMID: 32284020)
Ann Oncol. 2019 Dec 1;30(12):1856-1883. (PMID: 31549998)
Cancer Res. 2016 Apr 1;76(7):1804-13. (PMID: 26818109)
J Mol Diagn. 2017 Jan;19(1):4-23. (PMID: 27993330)
Nat Commun. 2014 Sep 10;5:4846. (PMID: 25204415)
J Clin Endocrinol Metab. 2013 Sep;98(9):E1562-6. (PMID: 23833040)
Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4519-24. (PMID: 19251651)
Bioinformatics. 2013 Jan 1;29(1):15-21. (PMID: 23104886)
JAMA. 2013 Apr 10;309(14):1493-501. (PMID: 23571588)
Mol Cancer. 2021 Oct 11;20(1):131. (PMID: 34635121)
Cancer Cell. 2018 Aug 13;34(2):242-255.e5. (PMID: 30107175)
Am J Surg Pathol. 2007 Aug;31(8):1256-64. (PMID: 17667551)
Cancer. 2021 Jun 1;127(11):1779-1787. (PMID: 33539547)
Nat Biotechnol. 2011 Jan;29(1):24-6. (PMID: 21221095)
Nat Commun. 2021 Oct 18;12(1):6058. (PMID: 34663816)
Genetics. 2023 May 4;224(1):. (PMID: 36866529)
J Exp Clin Cancer Res. 2014 Apr 11;33:33. (PMID: 24726063)
Int J Mol Sci. 2017 Jun 21;18(6):. (PMID: 28635633)
Thyroid. 2016 Jan;26(1):1-133. (PMID: 26462967)
Sci Signal. 2013 Apr 02;6(269):pl1. (PMID: 23550210)
J Clin Endocrinol Metab. 2021 Jul 13;106(8):2198-2207. (PMID: 34009369)
Cancer Res. 1988 Aug 15;48(16):4459-63. (PMID: 3293774)
معلومات مُعتمدة: S10 OD023475 United States OD NIH HHS; K12 CA090625 United States CA NCI NIH HHS; K08 CA240901 United States CA NCI NIH HHS; P30 DK058404 United States DK NIDDK NIH HHS; R01 CA281002 United States CA NCI NIH HHS; R35 GM122516 United States GM NIGMS NIH HHS; F30 CA281125 United States CA NCI NIH HHS; P30 EY008126 United States EY NEI NIH HHS; P30 DK020593 United States DK NIDDK NIH HHS; P30 CA068485 United States CA NCI NIH HHS; R01 CA272875 United States CA NCI NIH HHS; R01 CA244188 United States CA NCI NIH HHS; U24 DK059637 United States DK NIDDK NIH HHS
فهرسة مساهمة: Keywords: aggressive thyroid cancer; anaplastic thyroid carcinoma; cancer-associated fibroblasts; molecular biomarkers; next-generation sequencing; tumor immune microenvironment
تواريخ الأحداث: Date Created: 20231023 Latest Revision: 20240210
رمز التحديث: 20240210
مُعرف محوري في PubMed: PMC10589635
DOI: 10.1016/j.xgen.2023.100409
PMID: 37868034
قاعدة البيانات: MEDLINE
الوصف
تدمد:2666-979X
DOI:10.1016/j.xgen.2023.100409